SG Americas Securities LLC Has $857,000 Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

SG Americas Securities LLC increased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 116.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,270 shares of the company's stock after buying an additional 10,916 shares during the period. SG Americas Securities LLC's holdings in Vera Therapeutics were worth $857,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. First Turn Management LLC lifted its position in Vera Therapeutics by 53.3% in the third quarter. First Turn Management LLC now owns 326,494 shares of the company's stock worth $14,431,000 after purchasing an additional 113,550 shares during the period. Lord Abbett & CO. LLC grew its holdings in shares of Vera Therapeutics by 41.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock worth $18,830,000 after purchasing an additional 124,197 shares during the last quarter. Barclays PLC boosted its position in Vera Therapeutics by 94.1% in the 3rd quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after buying an additional 41,394 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Vera Therapeutics by 3.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company's stock valued at $15,992,000 after acquiring an additional 10,717 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Vera Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock valued at $44,415,000 after purchasing an additional 20,223 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently commented on VERA. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $107.00 target price on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Wells Fargo & Company initiated coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They issued an "overweight" rating and a $70.00 price target for the company. Scotiabank started coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $60.00 target price on the stock. Guggenheim lifted their price objective on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Finally, The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $58.00 target price for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $67.50.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $46.94, for a total transaction of $821,450.00. Following the completion of the transaction, the chief executive officer now directly owns 85,942 shares of the company's stock, valued at approximately $4,034,117.48. The trade was a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 52,500 shares of company stock valued at $2,305,625 over the last 90 days. 21.70% of the stock is owned by corporate insiders.

Vera Therapeutics Stock Up 5.4 %

VERA stock traded up $1.95 on Wednesday, hitting $37.93. 979,635 shares of the company's stock were exchanged, compared to its average volume of 762,807. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 12-month low of $31.77 and a 12-month high of $51.61. The stock has a market cap of $2.40 billion, a P/E ratio of -14.53 and a beta of 1.15. The firm has a 50 day moving average price of $42.18 and a two-hundred day moving average price of $40.91.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.21). As a group, equities research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.